Go Pro

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:SBOT

Stellar Biotechnologies (SBOT) Stock Price, News & Analysis

Stellar Biotechnologies logo

About Stellar Biotechnologies Stock (NASDAQ:SBOT)

Key Stats

Today's Range
$8.21
$8.99
50-Day Range
$4.44
$298,098.00
52-Week Range
$0.75
$3.25
Volume
4.26 million shs
Average Volume
2.95 million shs
Market Capitalization
$44.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein in Europe, North America, and Asia. The company offers KLH, an immune-stimulating protein used in the production of various immunotherapies; and as a carrier molecule or finished injectable product in the immunodiagnostic market. It provides its KLH protein under the Stellar KLH brand. The company's products include Stellar KLH protein in various grades, formulations, custom configurations, and fill finishes for drug development and research applications, as well as KLH-based in vitro diagnostic kits for research and preclinical use. Its customers and partners comprise biotechnology and pharmaceutical companies, academic institutions, clinical research organizations, and research centers. Stellar Biotechnologies, Inc. is based in Port Hueneme, California.

Receive SBOT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stellar Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SBOT Stock News Headlines

BlackRock and Vanguard already own THIS
Institutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 million shares worth about 716 million dollars, while Vanguard owns 48 million shares worth nearly 1.1 billion dollars. The company generates approximately 3.2 billion dollars in operating income against a market value of only about 8 billion dollars, and it has signed a multi-year AI agreement with Palantir to improve equipment reliability and well performance.tc pixel
Stellar Bancorp, Inc. Declares Quarterly Dividend
See More Headlines

SBOT Stock Analysis - Frequently Asked Questions

Stellar Biotechnologies Inc (NASDAQ:SBOT) posted its quarterly earnings data on Wednesday, May, 8th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by $0.05. The biotechnology company had revenue of $0.12 million for the quarter, compared to the consensus estimate of $0.11 million. Stellar Biotechnologies had a negative trailing twelve-month return on equity of 51.12% and a negative net margin of 1,782.64%.

Shares of Stellar Biotechnologies reverse split before market open on Monday, May 7th 2018.The 1-7 reverse split was announced on Friday, April 27th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 4th 2018. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Stellar Biotechnologies investors own include NexGen Energy (NXE), XOMA Royalty (XOMA), Anavex Life Sciences (AVXL), Eyepoint Pharmaceuticals (EYPT), OPKO Health (OPK) and Rigel Pharmaceuticals (RIGL).

Company Calendar

Last Earnings
5/08/2019
Today
9/14/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:SBOT
CIK
1540159
Fax
N/A
Employees
25
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($1.76)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$5.03 million
Net Margins
-1,782.64%
Pretax Margin
N/A
Return on Equity
-51.12%
Return on Assets
-48.37%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.24
Quick Ratio
8.96

Sales & Book Value

Annual Sales
$210 thousand
Price / Sales
212.44
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.12 per share
Price / Book
3.95

Miscellaneous

Outstanding Shares
5,330,000
Free Float
N/A
Market Cap
$44.61 million
Optionable
Not Optionable
Beta
N/A
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (NASDAQ:SBOT) was last updated on 9/14/2026 by MarketBeat.com Staff.
From Our Partners